Endothelin receptor antagonists for the treatment of pulmonary artery hypertension
Open Access
- 1 October 2012
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 91 (13-14) , 517-521
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular DiseaseJournal of Cardiovascular Pharmacology, 2000
- Activation of three types of voltage‐independent Ca2+ channel in A7r5 cells by endothelin‐1 as revealed by a novel Ca2+ channel blocker LOE 908British Journal of Pharmacology, 1999
- Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studiesCurrent Opinion in Nephrology and Hypertension, 1995
- Possible Role of Endothelin in Endothelial Regulation of Vascular ToneAnnual Review of Pharmacology and Toxicology, 1995
- Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertensionThe Journal of Pediatrics, 1993
- Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells.Stroke, 1991
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Endothelin-3 is a novel neuropeptide: Isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brainBiochemical and Biophysical Research Communications, 1989